Cell Biotech

049960 · KOSDAQ · Health Care · SMALL CAP

Provisional Q2 2026 results.

Cell Biotech filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$11.1M (+32.8% year on year), operating profit of US$1.15M (+28% year on year) and net income of US$2.54M (+1589.4% year on year).

Earnings(Operating results (consolidated) (preliminary) (fair disclosure))· FILED 2026-08-07· RCEPT 20260807900323

US$11.1MRevenue
+32.8%Revenue vs a year earlier
US$1.15MOperating profit

Converted at 1 USD ≈ ₩1,422.3 (filing-date rate, 2026-08-06 close)

What happened

Cell Biotech filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$11.1M (+32.8% year on year), operating profit of US$1.15M (+28% year on year) and net income of US$2.54M (+1589.4% year on year).

These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.

RevenueUS$11.1M
Revenue vs a year earlier+32.8%
Operating profitUS$1.15M
Net incomeUS$2.54M
PeriodQ2 2026 (consolidated)
Filed2026-08-07, Operating results (consolidated) (preliminary) (fair disclosure)
SourceDART rcept 20260807900323 → open original filing

Source: DART. Information only, not investment advice.

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-08-07 (KST). · Converted at 1 USD ≈ ₩1,325 (rate of 2026-10-21).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.